RecruitingNCT06724315

Prospective and Multicentric Cohort Study of Severe and Very Severe Chronic Obstructive Pulmonary Disease (COPD) in Brazil (SCOPe).


Sponsor

Hospital Israelita Albert Einstein

Enrollment

693 participants

Start Date

Jan 31, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Chronic obstructive pulmonary disease (COPD) is prevalent (8-20%) and is one of the leading causes of mortality. In 2019 according to WHO it was the third highest cause of death worldwide. In 2019 in Brazil respiratory diseases (Chapter J in the ICD10) were the third cause of death (176.073) with COPD (J44) accounting for 45.163 deaths (25,6% of respiratory and 3% overall). There is an upward trend for COPD mortality worldwide. The disease also has a high morbidity leading to impairment in daily activity and quality of life. Patients with severe and very severe disease are at a higher risk for negative outcomes, including exacerbation (up to 2-3 per patient per year). This in turn increases the risk of future exacerbations and mortality, with heightened risk lasting up to two years after each event. It is impertive to evaluate which sub-groups are at an even higher risk and could be potential targets for intervention. "The PLATINO study" was conducted on 2004 and evaluated the prevalence of COPD in 5 cities, only one in Brazil - Sao Paulo. As the data is 20 years old it might not reflect the current epidemiological status and might not be representative of Brazil as a whole. Understanding this population, their clinical and laboratorial characteristics can help identify sub-groups with higher risk and potential for intervention. The current prevalence, causing agent and characteristics are not known in Brazil as well as detailed outcome data.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This Brazilian study follows patients with severe or very severe COPD (chronic obstructive pulmonary disease) to better understand disease progression, treatment patterns, and outcomes in real-world settings. **You may be eligible if...** - Have severe or very severe COPD (as defined by GOLD criteria: significant breathing limitation, frequent flare-ups, or significant symptoms) - Exposed to known COPD risk factors and have an abnormal breathing test (FEV1/FVC ratio below 0.7) **You may NOT be eligible if...** - Have severe interstitial lung disease (scarring of the lungs) - Have another serious lung condition that is the primary cause of your breathing problems - Are unable or unwilling to attend follow-up visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Hospital Israelita Albert Einstein (HIAE)

São Paulo, São Paulo, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06724315


Related Trials